Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-cash Items (2021 - 2025)

Kiniksa Pharmaceuticals International's Non-cash Items history spans 5 years, with the latest figure at $213.3 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 242.18% year-over-year to $213.3 million; the TTM value through Dec 2025 reached $213.3 million, up 242.18%, while the annual FY2025 figure was $213.3 million, 242.18% up from the prior year.
  • Non-cash Items reached $213.3 million in Q4 2025 per KNSA's latest filing, up from $6.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $213.3 million in Q4 2025 to a low of $4.4 million in Q1 2021.
  • Average Non-cash Items over 5 years is $23.6 million, with a median of $7.1 million recorded in 2023.
  • The largest YoY upside for Non-cash Items was 242.18% in 2025 against a maximum downside of 12.67% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $14.9 million in 2021, then soared by 118.33% to $32.6 million in 2022, then soared by 67.47% to $54.7 million in 2023, then increased by 14.05% to $62.3 million in 2024, then soared by 242.18% to $213.3 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Non-cash Items are $213.3 million (Q4 2025), $6.6 million (Q3 2025), and $7.2 million (Q2 2025).